Experimental Models Used to Study Human Tuberculosis

Advances in Applied Microbiology

Volumn 71, Issue , 2010, Pages 75-89

  O'Toole, Ronan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CELL CULTURE; DISEASE MODEL; GUINEA PIG; HUMAN; LUNG TUBERCULOSIS; MACROPHAGE; MICROBIOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PATHOPHYSIOLOGY; REVIEW; TUBERCULOSIS;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 77952316129     PISSN: 00652164     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2164(10)71003-0     Document Type: Chapter

References (82)

1. Ahmad, Z., Klinkenberg, L.G., Pinn, M.L., Fraig, M.M., Peloquin, C.A., Bishai, W.R., Nuermberger, E.L., Grosset, J.H., Karakousis, P.C., Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200 (2009), 1136–1143.
2. Aly, S., Wagner, K., Keller, C., Malm, S., Malzan, A., Brandau, S., Bange, F.C., Ehlers, S., Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210 (2006), 298–305.
3. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 (2005), 223–227.
4. Anes, E., Peyron, P., Staali, L., Jordao, L., Gutierrez, M.G., Kress, H., Hagedorn, M., Maridonneau-Parini, I., Skinner, M.A., Wildeman, A.G., Kalamidas, S.A., Kuehnel, M., Griffiths, G., Dynamic life and death interactions between Mycobacterium smegmatis and J774 macrophages. Cell Microbiol. 8 (2006), 939–960.
5. Anuchin, A.M., Mulyukin, A.L., Suzina, N.E., Duda, V.I., El-Registan, G.I., Kaprelyants, A.S., Dormant forms of Mycobacterium smegmatis with distinct morphology. Microbiology 155 (2009), 1071–1079.
6. Bange, F.C., Collins, F.M., Jacobs, W.R. Jr., Survival of mice infected with Mycobacterium smegmatis containing large DNA fragments from Mycobacterium tuberculosis. Tuber. Lung Dis. 79 (1999), 171–180.
7. Barry, C.E. 3rd, Response to: Mycobacterium smegmatis: An absurd model for tuberculosis?. Trends Microbiol. 9 (2001), 473–474.
8. Barry, C.E. 3rd, Unorthodox approach to the development of a new antituberculosis therapy. N. Engl. J. Med. 360 (2009), 2466–2467.
9. Barry, C.E. 3rd, Boshoff, H.I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R.J., Young, D., The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7 (2009), 845–855.
10. Betts, J.C., Lukey, P.T., Robb, L.C., McAdam, R.A., Duncan, K., Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43 (2002), 717–731.
11. Brock, T., Robert Koch: A life in medicine and bacteriology. 1999, American Society for Microbiology, Washington, DC.
12. Brosch, R., Gordon, S.V., Marmiesse, M., Brodin, P., Buchrieser, C., Eiglmeier, K., Garnier, T., Gutierrez, C., Hewinson, G., Kremer, K., Parsons, L.M., Pym, A.S., et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. USA 99 (2002), 3684–3689.
13. Brown-Elliott, B.A., Wallace, R.J. Jr., Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin. Microbiol. Rev. 15 (2002), 716–746.
14. Casart, Y., Gamero, E., Rivera-Gutierrez, S., Gonzalez, Y.M.J.A., Salazar, L., par genes in Mycobacterium bovis and Mycobacterium smegmatis are arranged in an operon transcribed from “SigGC” promoters. BMC Microbiol., 8, 2008, 51.
15. Cho, S.H., Warit, S., Wan, B., Hwang, C.H., Pauli, G.F., Franzblau, S.G., Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51 (2007), 1380–1385.
16. Christophe, T., Jackson, M., Jeon, H.K., Fenistein, D., Contreras-Dominguez, M., Kim, J., Genovesio, A., Carralot, J.P., Ewann, F., Kim, E.H., Lee, S.Y., Kang, S., et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog., 5, 2009, e1000645.
17. Converse, P.J., Karakousis, P.C., Klinkenberg, L.G., Kesavan, A.K., Ly, L.H., Allen, S.S., Grosset, J.H., Jain, S.K., Lamichhane, G., Manabe, Y.C., McMurray, D.N., Nuermberger, E.L., Bishai, W.R., Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect. Immun. 77 (2009), 1230–1237.
18. de Chastellier, C., The many niches and strategies used by pathogenic mycobacteria for survival within host macrophages. Immunobiology, 2009.
19. Deb, C., Lee, C.M., Dubey, V.S., Daniel, J., Abomoelak, B., Sirakova, T.D., Pawar, S., Rogers, L., Kolattukudy, P.E., A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE, 4, 2009, e6077.
20. Dellagostin, O.A., Esposito, G., Eales, L.J., Dale, J.W., McFadden, J., Activity of mycobacterial promoters during intracellular and extracellular growth. Microbiology 141:Pt 8 (1995), 1785–1792.
21. Dick, T., Lee, B.H., Murugasu-Oei, B., Oxygen depletion induced dormancy in Mycobacterium smegmatis. FEMS Microbiol. Lett. 163 (1998), 159–164.
22. Drumm, J.E., Mi, K., Bilder, P., Sun, M., Lim, J., Bielefeldt-Ohmann, H., Basaraba, R., So, M., Zhu, G., Tufariello, J.M., Izzo, A.A., Orme, I.M., Almo, S.C., Leyh, T.S., Chan, J., Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-Binding: Requirement for establishing chronic persistent infection. PLoS Pathog., 5, 2009, e1000460.
23. Dye, C., Scheele, S., Dolin, P., Pathania, V., Raviglione, M.C., Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 (1999), 677–686.
24. Flynn, J.L., Capuano, S.V., Croix, D., Pawar, S., Myers, A., Zinovik, A., Klein, E., Non-human primates: A model for tuberculosis research. Tuberculosis (Edinb) 83 (2003), 116–118.
25. Gordhan, B.G., Smith, D.A., Alderton, H., McAdam, R.A., Bancroft, G.J., Mizrahi, V., Construction and phenotypic characterization of an auxotrophic mutant of Mycobacterium tuberculosis defective in L-arginine biosynthesis. Infect. Immun. 70 (2002), 3080–3084.
26. Gupta, U.D., Katoch, V.M., Animal models of tuberculosis. Tuberculosis (Edinb) 85 (2005), 277–293.
27. Gupta, U.D., Katoch, V.M., Animal models of tuberculosis for vaccine development. Indian J. Med. Res. 129 (2009), 11–18.
28. Gutierrez, M.G., Mishra, B.B., Jordao, L., Elliott, E., Anes, E., Griffiths, G., NF-kappa B activation controls phagolysosome fusion-mediated killing of mycobacteria by macrophages. J. Immunol. 181 (2008), 2651–2663.
29. Hampshire, T., Soneji, S., Bacon, J., James, B.W., Hinds, J., Laing, K., Stabler, R.A., Marsh, P.D., Butcher, P.D., Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: A model for persistent organisms?. Tuberculosis (Edinb) 84 (2004), 228–238.
30. Haydel, S.E., Clark-Curtiss, J.E., Global expression analysis of two-component system regulator genes during Mycobacterium tuberculosis growth in human macrophages. FEMS Microbiol. Lett. 236 (2004), 341–347.
31. Hershkovitz, I., Donoghue, H.D., Minnikin, D.E., Besra, G.S., Lee, O.Y., Gernaey, A.M., Galili, E., Eshed, V., Greenblatt, C.L., Lemma, E., Bar-Gal, G.K., Spigelman, M., Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS ONE, 3, 2008, e3426.
32. Hondalus, M.K., Bardarov, S., Russell, R., Chan, J., Jacobs, W.R. Jr., Bloom, B.R., Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 68 (2000), 2888–2898.
33. Jakimowicz, D., Brzostek, A., Rumijowska-Galewicz, A., Zydek, P., Dolzblasz, A., Smulczyk-Krawczyszyn, A., Zimniak, T., Wojtasz, L., Zawilak-Pawlik, A., Kois, A., Dziadek, J., Zakrzewska-Czerwinska, J., Characterization of the mycobacterial chromosome segregation protein ParB and identification of its target in Mycobacterium smegmatis. Microbiology 153 (2007), 4050–4060.
34. Jordao, L., Bleck, C.K., Mayorga, L., Griffiths, G., Anes, E., On the killing of mycobacteria by macrophages. Cell Microbiol. 10 (2008), 529–548.
35. Khan, A., Sarkar, D., A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. J. Microbiol. Methods 73 (2008), 62–68.
36. Khan, A., Sarkar, S., Sarkar, D., Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. Int. J. Antimicrob. Agents 32 (2008), 40–45.
37. Kharatmal, S., Jhamb, S.S., Singh, P.P., Evaluation of BACTEC 460 TB system for rapid in vitro screening of drugs against latent state Mycobacterium tuberculosis H37Rv under hypoxia conditions. J. Microbiol. Methods 78 (2009), 161–164.
38. Klinkenberg, L.G., Sutherland, L.A., Bishai, W.R., Karakousis, P.C., Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198 (2008), 275–283.
39. Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Gohlmann, H.W., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D., Andries, K., Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283 (2008), 25273–25280.
40. Kritski, A.L., de Melo, F.A.F., Palomino, J.C., Leao, S.C., Ritacco, V., (eds.) Tuberculosis 2007; from basic science to patient care, 2007 http://www.tuberculosistextbook.com.
41. Lenaerts, A.J., Gruppo, V., Marietta, K.S., Johnson, C.M., Driscoll, D.K., Tompkins, N.M., Rose, J.D., Reynolds, R.C., Orme, I.M., Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49 (2005), 2294–2301.
42. Lenaerts, A.J., Hoff, D., Aly, S., Ehlers, S., Andries, K., Cantarero, L., Orme, I.M., Basaraba, R.J., Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51 (2007), 3338–3345.
43. Lin, P.L., Rodgers, M., Smith, L., Bigbee, M., Myers, A., Bigbee, C., Chiosea, I., Capuano, S.V., Fuhrman, C., Klein, E., Flynn, J.L., Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77 (2009), 4631–4642.
44. Lonnroth, K., Raviglione, M., Global epidemiology of tuberculosis: Prospects for control. Semin. Respir. Crit. Care Med. 29 (2008), 481–491.
45. Lonnroth, K., Jaramillo, E., Williams, B.G., Dye, C., Raviglione, M., Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Soc. Sci. Med. 68 (2009), 2240–2246.
46. Lougheed, K.E., Taylor, D.L., Osborne, S.A., Bryans, J.S., Buxton, R.S., New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb) 89 (2009), 364–370.
47. Mayuri, B.G., Das, T.K., Tyagi, J.S., Molecular analysis of the dormancy response in Mycobacterium smegmatis: Expression analysis of genes encoding the DevR-DevS two-component system, Rv3134c and chaperone alpha-crystallin homologues. FEMS Microbiol. Lett. 211 (2002), 231–237.
48. McMurray, D.M., Guinea pig model of tuberculosis. Bloom, B.R., (eds.) Tuberculosis: Pathogenesis, protection, and control, 1994, American Society for Microbiology, Washington, DC.
49. Murphy, D.J., Brown, J.R., Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect. Dis., 7, 2007, 84.
50. National Institute of Allergy and Infectious Diseases. N. I. o. H., Understanding Microbes in Sickness and in Health, 2006.
51. Nyka, W., Method for staining both acid-fast and chromophobic tubercle bacilli with carbolfuschsin. J. Bacteriol. 93 (1967), 1458–1460.
52. Nyka, W., Studies on the effect of starvation on mycobacteria. Infect. Immun. 9 (1974), 843–850.
53. Orme, I.M., Collins, F.M., Mouse model of tuberculosis. Bloom, B.R., (eds.) Tuberculosis: Pathogenesis, Protection, and Control, 1994, American Society for Microbiology, Washington, DC.
54. O'Toole, R., Smeulders, M.J., Blokpoel, M.C., Kay, E.J., Lougheed, K., Williams, H.D., A two-component regulator of universal stress protein expression and adaptation to oxygen starvation in Mycobacterium smegmatis. J. Bacteriol. 185 (2003), 1543–1554.
55. Parrish, N.M., Dick, J.D., Bishai, W.R., Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6 (1998), 107–112.
56. Pethe, K., Swenson, D.L., Alonso, S., Anderson, J., Wang, C., Russell, D.G., Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc. Natl. Acad. Sci. USA 101 (2004), 13642–13647.
57. Recht, J., Kolter, R., Glycopeptidolipid acetylation affects sliding motility and biofilm formation in Mycobacterium smegmatis. J. Bacteriol. 183 (2001), 5718–5724.
58. Recht, J., Martinez, A., Torello, S., Kolter, R., Genetic analysis of sliding motility in Mycobacterium smegmatis. J. Bacteriol. 182 (2000), 4348–4351.
59. Reyrat, J.M., Kahn, D., Mycobacterium smegmatis: An absurd model for tuberculosis?. Trends Microbiol. 9 (2001), 472–474.
60. Rohde, K.H., Abramovitch, R.B., Russell, D.G., Mycobacterium tuberculosis invasion of macrophages: Linking bacterial gene expression to environmental cues. Cell Host Microbe 2 (2007), 352–364.
61. Russell, D.G., Mycobacterium tuberculosis: Here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2 (2001), 569–577.
62. Selwyn, P.A., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E.E., Klein, R.S., Davenny, K., Friedland, G.H., Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N. Engl. J. Med. 327 (1992), 1697–1703.
63. Skeiky, Y.A., Dietrich, J., Lasco, T.M., Stagliano, K., Goetz, M.A., Cantarero, L., Basaraba, R.J., Bang, P., Kromann, I., McClain, B.M., Sadoff, J.C., Andersen, P., Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine, 2009.
64. Smeulders, M.J., Keer, J., Speight, R.A., Williams, H.D., Adaptation of Mycobacterium smegmatis to stationary phase. J. Bacteriol. 181 (1999), 270–283.
65. Smith, D., Wiegeshaus, E., Balasubramanian, V., Animal models for experimental tuberculosis. Clin. Infect. Dis. 31:Suppl 3 (2000), S68–S70.
66. Sneader, W., Drug discovery, a history. 2005, Wiley, Chichester, UK.
67. Stewart, G.R., Patel, J., Robertson, B.D., Rae, A., Young, D.B., Mycobacterial mutants with defective control of phagosomal acidification. PLoS Pathog. 1 (2005), 269–278.
68. Tsai, M.C., Chakravarty, S., Zhu, G., Xu, J., Tanaka, K., Koch, C., Tufariello, J., Flynn, J., Chan, J., Characterization of the tuberculous granuloma in murine and human lungs: Cellular composition and relative tissue oxygen tension. Cell Microbiol. 8 (2006), 218–232.
69. Tyagi, J.S., Sharma, D., Mycobacterium smegmatis and tuberculosis. Trends Microbiol. 10 (2002), 68–69.
70. Via, L.E., Lin, P.L., Ray, S.M., Carrillo, J., Allen, S.S., Eum, S.Y., Taylor, K., Klein, E., Manjunatha, U., Gonzales, J., Lee, E.G., Park, S.K., et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76 (2008), 2333–2340.
71. Vonmoos, S., Leuenberger, P., Beer, V., de Haller, R., Pleuropulmonary infection caused by Mycobacterium smegmatis. Case description and literature review. Schweiz. Med. Wochenschr. 116 (1986), 1852–1856.
72. Vynnycky, E., Fine, P.E., Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152 (2000), 247–263.
73. Waagmeester, A., Thompson, J., Reyrat, J.M., Identifying sigma factors in Mycobacterium smegmatis by comparative genomic analysis. Trends Microbiol. 13 (2005), 505–509.
74. Waddell, S.J., Butcher, P.D., Microarray analysis of whole genome expression of intracellular Mycobacterium tuberculosis. Curr. Mol. Med. 7 (2007), 287–296.
75. Wallace, R.J. Jr., Nash, D.R., Tsukamura, M., Blacklock, Z.M., Silcox, V.A., Human disease due to Mycobacterium smegmatis. J. Infect. Dis. 158 (1988), 52–59.
76. Wayne, L.G., Hayes, L.G., An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64 (1996), 2062–2069.
77. Wayne, L.G., Sohaskey, C.D., Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55 (2001), 139–163.
78. WHO. World Health Organisation and the Stop TB Partnership. Global Plan to Stop TB, 2006.
79. WHO. World Health Organisation Report 2009, Global Tuberculosis Control: Epidemiology; Strategy; Financing, 2009.
80. Williams, A., Hall, Y., Orme, I.M., Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb) 89 (2009), 389–397.
81. Wirth, T., Hildebrand, F., Allix-Beguec, C., Wolbeling, F., Kubica, T., Kremer, K., van Soolingen, D., Rusch-Gerdes, S., Locht, C., Brisse, S., Meyer, A., Supply, P., Niemann, S., Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog., 4, 2008, e1000160.
82. Young, D., Animal models of tuberculosis. Eur. J. Immunol. 39 (2009), 2011–2014.